Research & Development

Our Commitment to Expanding Access to Life-saving Treatment Options

At Apobiologix, we understand invention is not the only way to innovate. It's this forward thinking that puts our Research and Development team on the leading edge of biosimilar product development.

The foundation for our future growth is well established

Our first 2 products are short- and long-acting G-CSF biosimilars.

We launched Grastofil® (filgrastim), biosimilar to Neupogen in Europe in 2014. In 2016, Apobiologix also launched Grastofil in Canada. In April 2018, Lapelga™ (pegfilgrastim) biosimilar to Neulasta® was approved in Canada. This is the first approval of biosimilar pegfilgrastim in Canada and in the world. The FDA is actively reviewing our applications for both Apobiologix pegfilgrastim, biosimilar to Neulasta® and Apobiologix filgrastim, biosimilar to Neupogen® for use in the United States.

Our Pipeline: A commitment to expanding access to life-saving treatment options

Product Development Waves

We are continually exploring additional therapeutic proteins for developmental consideration.


Invention is not the only innovation.

Apobiologix logo

2400 North Commerce Parkway,
Suite 300,
Weston, Florida 33326



Grastofil® is a registered trademark of Apotex Technologies Inc.
Lapelga™ is a trademark of Apotex Technologies Inc.
Critalfa™ is a trademark of Apotex Technologies Inc.
Neupogen® and Neulasta® and Epogen® and Aranesp® are registered trademarks of Amgen Inc.
Procrit® is a registered trademark of Janssen Products, LP.
Herceptin® and Avastin® are registered trademarks of Genentech USA, Inc.
Rituxan® is a registered trademark of Biogen.